Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 175

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Persistence of the treatment effect of idebenone in Leber’s hereditary optic neuropathy

Open access
Klopstock, T., Metz, G., Yu-Wai-Man, P., Büchner, B., Gallenmüller, C., Bailie, M., Nwali, N., Griffiths, P. G., von Livonius, B., Reznicek, L., Rouleau, J., Coppard, N., Meier, T., Chinnery, P. F.·2013·Brain

Abstract

Sir, There is a growing body of evidence supporting the beneficial effects of idebenone in Leber’s hereditary optic neuropathy (LHON, MIM 353500), an inherited mitochondrial disease that causes rapid bilateral vision loss and lifelong legal blindness. Until recently, reports were limited to isolated case studies and small open-label case series (Mashima et al., 1992, 2000; Cortelli et al., 1997; Carelli et al., 1998, 2001; Barnils et al., 2007). However, in 2011, two articles published in Brain provided additional evidence for the therapeutic use of idebenone in LHON (Carelli et al., 2011; Klopstock et al., 2011). In the first complete randomized, placebo-controlled, double-blind clinical trial in LHON [Rescue of Hereditary Optic Disease Outpatient Study (RHODOS), ClinicalTrials.gov identifier: NCT00747487], 85 unselected patients with LHON ≥14 years of age were randomized to receive 900 mg/day of idebenone or placebo in a 2:1 ratio for 24 weeks (Klopstock et al., 2011). In the intent-to-treat population, visual acuity data were available for 82 patients harbouring one of the three primary mitochondrial DNA mutations (m.11778G>A, m.3460G>A and m.14484T>C) and experiencing first vision loss up to 5 years before study enrolment. All visual acuity end-points in the intent-to-treat population showed a consistent trend, with idebenone protecting patients from further vision loss, in contrast to the placebo group where visual acuity continued to deteriorate. Efficacy seen on visual acuity end-points was supported by independent measures including tests of colour contrast sensitivity. Following a pre-specified analysis by mutation, exclusion of patients with the m.14484T>C mutation, which is known for its high spontaneous recovery rate, resulted in a larger treatment effect in all visual acuity end-points. This finding was in agreement with the data from a retrospective analysis of 103 patients, published in the same issue of Brain (Carelli et al., 2011). This study showed a significant difference in the incidence of visual recovery in idebenone-treated patients harbouring the m.11778G>A mitochondrial DNA mutation, known to cause ∼70% of LHON cases in Europe, and concluded that an early treatment start is recommended. Vision loss in LHON is rapid, and in the majority of cases results in persistent lifelong visual impairment, typically rendering patients legally blind. Therefore, in light of the relatively short treatment duration of 24 weeks for RHODOS, we have now determined whether the observed treatment effects persisted after discontinuation of treatment. For this, we invited patients previously participating in RHODOS for reassessment of their visual acuity to a single visit observational follow-up study (RHODOS-OFU), which had ethical and institutional review board approval and was sponsored by Santhera Pharmaceuticals (ClinicalTrials.gov identifier: NCT01421381). According to the study protocol, the primary end-point was the change in best (logMAR) visual acuity at this study visit compared with baseline and Week 24 of RHODOS. Sixty patients (70.6%) who participated in RHODOS were enrolled into this RHODOS–OFU study, of whom 58 patients provided visual acuity data in both studies and were included in the analysis. Of these, 39 patients had been randomized to idebenone in the course of RHODOS and 19 patients to placebo, in keeping with the 2:1 ratio of idebenone:placebo in the RHODOS study design. There were no significant differences in the demographics or molecular genetic characteristics of the RHODOS–OFU group compared with the original RHODOS cohort (Table 1), indicating that the smaller subpopulation recruited to the RHODOS–OFU study was representative of the RHODOS study population. The mean ± SD time that had elapsed between Week 24 of RHODOS and the RHODOS–OFU study visit was 30.5 ± 4.9 months (median: 30.1 months). The time since onset of vision loss at baseline of RHODOS for this subpopulation was 23 ± 17 months (median: 18 months). Demographics of patients enrolled in the RHODOS study compared with the RHODOS observational follow-up study a Former treatment group in RHODOS study. b Percentage RHODOS–OFU population relative to the corresponding group from the RHODOS intent-to-treat population. c At RHODOS baseline. d For RHODOS based on efficacy population, n = 82 (53 idebenone, 29 placebo). e Off-chart defined as >logMAR 1.68 and applying logMAR 2.0/2.3/2.6 for counting fingers/hand motion/light perception. BL = baseline. Demographics of patients enrolled in the RHODOS study compared with the RHODOS observational follow-up study a Former treatment group in RHODOS study. b Percentage RHODOS–OFU population relative to the corresponding group from the RHODOS intent-to-treat population. c At RHODOS baseline. d For RHODOS based on efficacy population, n = 82 (53 idebenone, 29 placebo). e Off-chart defined as >logMAR 1.68 and applying logMAR 2.0/2.3/2.6 for counting fingers/hand motion/light perception

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/brain/aws279

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 175

Metadata

Authors
Klopstock, T., Metz, G., Yu-Wai-Man, P., Büchner, B., Gallenmüller, C., Bailie, M., Nwali, N., Griffiths, P. G., von Livonius, B., Reznicek, L., Rouleau, J., Coppard, N., Meier, T., & Chinnery, P. F.
Venue
Brain
Published
2013-02
Volume
136
Issue
2
Pages
e230-e230
ISSN
  • 0006-8950 (ISSN-L)
  • 1460-2156
OpenAlex
W2112249409
Cited by
175
References
1
FWCI
8.03
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.